Literature DB >> 1729301

Contrast-enhanced MRA of the brain.

G Marchal1, J Michiels, H Bosmans, P Van Hecke.   

Abstract

Most sequences for MR angiography (MRA) used today exploit the macroscopic motion of the blood to differentiate vessels from the stationary tissues. An alternative approach to inflow based MRA is contrast enhanced MRA, in which relaxation agents are used to selectively shorten the T1 of the blood below the T1 value of the stationary tissues. We have evaluated cerebral Gd enhanced MRA, comparing it with conventional angiography and noncontrast inflow based MRA. Contrast/enhanced MRAs were obtained at 1.0 T with a 3D FISP sequence with TR/TE/alpha: 35-40 ms, 7-11 ms/TE/25 degrees. Contrast enhancement was obtained by a biphasic injection of a double dose of Gd-DOTA (0.2 mmol/kg) during image acquisition. With the described technique the conspicuity of both cerebral arteries and veins is improved compared to nonenhanced inflow MRA.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1729301     DOI: 10.1097/00004728-199201000-00005

Source DB:  PubMed          Journal:  J Comput Assist Tomogr        ISSN: 0363-8715            Impact factor:   1.826


  12 in total

1.  MR digital subtraction angiography of cerebral arteriovenous malformations.

Authors:  K Tsuchiya; S Katase; A Yoshino; J Hachiya
Journal:  AJNR Am J Neuroradiol       Date:  2000-04       Impact factor: 3.825

2.  [Significance of MR angiography for imaging diagnostics of carotid artery diseases].

Authors:  L Schuster; T Hauser; M Essig
Journal:  Radiologe       Date:  2010-07       Impact factor: 0.635

Review 3.  MR angiography of the intracranial vessels: technical aspects and clinical applications.

Authors:  Ozkan Ozsarlak; Johan W Van Goethem; Menno Maes; Paul M Parizel
Journal:  Neuroradiology       Date:  2004-12-04       Impact factor: 2.804

4.  Three-dimensional dynamic magnetic resonance angiography for the evaluation of radiosurgically treated cerebral arteriovenous malformations.

Authors:  Jean-Yves Gauvrit; Catherine Oppenheim; Francois Nataf; Olivier Naggara; Denis Trystram; Thierry Munier; Daniel Fredy; Jean-Pierre Pruvo; François-Xavier Roux; Xavier Leclerc; Jean-François Meder
Journal:  Eur Radiol       Date:  2005-10-12       Impact factor: 5.315

5.  Magnetic resonance angiography of the carotid arteries: comparison of unenhanced and contrast enhanced techniques.

Authors:  Harald Kramer; Val M Runge; John N Morelli; Kenneth D Williams; L Gill Naul; Konstantin Nikolaou; Maximilian F Reiser; Bernd J Wintersperger
Journal:  Eur Radiol       Date:  2011-04-09       Impact factor: 5.315

6.  Quiz case of the month. Cerebral deep vein thrombosis.

Authors:  K Okamoto; J Ito; T Furusawa; K Sakai; K Ono; M Watanabe; S Tokiguchi
Journal:  Eur Radiol       Date:  1998       Impact factor: 5.315

7.  The role of contrast-enhanced MR angiography in the assessment of recently ruptured intracranial aneurysms: a comparative study.

Authors:  Ercument Unlu; Bilge Cakir; Burak Gocer; Nermin Tuncbilek; Murat Gedikoglu
Journal:  Neuroradiology       Date:  2005-07-30       Impact factor: 2.804

8.  3D time-of-flight MR angiography of the intracranial vessels: optimization of the technique with water excitation, parallel acquisition, eight-channel phased-array head coil and low-dose contrast administration.

Authors:  O Ozsarlak; J W Van Goethem; P M Parizel
Journal:  Eur Radiol       Date:  2004-07-31       Impact factor: 5.315

9.  Magnetic resonance angiography of supratentorial tumours: comparison with selective digital subtraction angiography.

Authors:  G Wilms; H Bosmans; G Marchal; P Demaerel; J Goffin; C Plets; A L Baert
Journal:  Neuroradiology       Date:  1995-01       Impact factor: 2.804

10.  Gadodiamide injection at 0.1 and 0.3 mmol/kg body weight: a phase III double-blind, parallel, randomised clinical investigation of known or suspected central nervous system lesions at 1.5 T.

Authors:  P Demaerel; G Marchal; G Wilms; F Van Calenbergh; D De Greef; A Børseth; A L Baert
Journal:  Neuroradiology       Date:  1994-07       Impact factor: 2.804

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.